Navigation Links
Shire plc : Second Quarter 2011 Results Date Notification - July 28, 2011
Date:7/15/2011

DUBLIN, July 15, 2011 /PRNewswire/ --


 

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce second quarter 2011 earnings on Thursday July 28, 2011.

Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:00 BST/9:00 EDT.

The details of the conference call are as follows:

UK dial in: 0800-077-8492 or 0844-335-0351 US dial in: +1-866-8048688 or +1-718-3541175 International dial in: +44-208-974-7900

Global Access Numbers:    http://www.btconferencing.com/globalaccess/?bid=54_attended

Password/Conf ID:    818 608

Live Webcast:    http://www.shire.com/shireplc/en/investors

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year.  Details can be found on our Investor Relations website http://www.shire.com/shireplc/en/investors.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact:

Investor Relations Souheil Salah (ssalah@shire.com) +44-1256-894-160 Erin Kelly (erikelly@shire.com) +1-781-482-9541


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents
2. United Lincolnshire Hospitals NHS Trust Selects Jayex QI Interactive Patient Survey and Information Management Kiosk
3. Shire Completes Acquisition of Advanced BioHealing, Inc.
4. European Authorities Approve New Manufacturing Facility for Shires REPLAGAL® (agalsidase alfa)
5. Prasco Announces Agreement with Shire for Future Exclusive Distribution and Supply of Authorized Generic for PENTASA®
6. Shire Recognized by ISPE Facility of the Year Awards Program
7. Reportlinker Adds Shire plc: PharmaVitae Profile
8. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
9. Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010
10. Atrium Recognized by New Hampshire Bio/Medical Council
11. Shire Update on ProAmatine(R) (midodrine HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The Texas ... in recently to the labor and delivery team at Women’s Hospital at Renaissance in ... who give birth at the hospital and decide to donate. , “Women’s Hospital ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... , ... Intellitec Solutions announced the publication of a case ... GP solution that integrates to their PointClickCare EHR software package. With the guidance ... Grove now has the capability to achieve its goal for a comprehensive EHR ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s ... is the premier online modeling resource for fluorescence microscopists and optical system designers, ... during last 5 years spanning the globe, SearchLight has become a tremendously popular ...
Breaking Medicine News(10 mins):